Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 11:43:72.
doi: 10.11604/pamj.2022.43.72.35450. eCollection 2022.

Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12th week of treatment: a cross-sectional study

Donatien Serge Mbaga  1 , Jacky Njiki Bikoï  1 , Etienne Atenguena Okobalemba  2 , Justin Olivier Essindi  1 , Chris André Mbongue Mikangue  1 , Alexandra Emmanuelle Membangbi  1 , Aïcha Ngoutane  1   3 , Arnaud Franck Elang  1 , Sabine Aimée Touangnou-Chamda  1 , Carole Stéphanie Sake  1 , George Ikomey Mondinde  4 , Sebastien Kenmoe  5 , Sara Honorine Riwom Essama  1
Affiliations

Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12th week of treatment: a cross-sectional study

Donatien Serge Mbaga et al. Pan Afr Med J. .

Abstract

Introduction: epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12th week of treatment.

Methods: during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY). Five millilitres of blood samples were taken from each consenting participant and then a qualitative search for HCV Ag by Enzyme-Linked Immuno Assay (ELISA) was performed. Analysis of the results was performed using SPSS Version 25.0 software.

Results: out of the 192 participants selected for the study, only 92 (47,9%) participants were at 12 weeks of treatment, including 69 (75%) participants positive for the hepatitis C virus antibody (HCV Ab) by RDT. Of these participants, 44 (47.8%) participants were positive for HCV Ag by ELISA, respectively 19/37 (51.3%), 14/19 (73.6%), 11/13 (84.6%) with chronic hepatitis (HC), Cirrhosis, and HCC (P<0.0001).

Conclusion: our results showed a high prevalence of HCV Ag in patients at their 12th week of treatment which predicts treatment failure and calls for public policy to develop new management strategies to prevent HCV treatment failure in our context.

Keywords: Hepatitis C virus Ag; chronic hepatitis; cirrhosis; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
flow Chart of selection of participants
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. WHO . 2022. Hepatitis: overview. Accessed April 13 2022.
    1. WHO Hepatitis C. 2021. Accessed April 26 2022.
    1. Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, et al. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study. PLoS ONE. 2018;13(4):e0196301. - PMC - PubMed
    1. Mbaga DS, Kenmoe S, Kengne-Ndé C, Ebogo-Belobo JT, Mahamat G, Foe-Essomba JR, et al. Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: a meta-analysis including sensitivity analyses for studies comparable for confounders. PLoS One. 2022;17(1):e0262903. - PMC - PubMed
    1. Organisation mondiale de la Santé Comité Régional Afrique Rapport de situation sur la mise en œuvre du cadre d´action de la stratégie mondiale du secteur de la santé pour la prévention, les soins et le traitement de l´hépatite virale 2016-2021 dans la région Africaine. Bureau Régional de l´Afrique. 2018. Accessed April 16 2022.

Substances